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Abstract
One of the main limitations of intracranial models of
diseases is our present inability to monitor and
evaluate the intracranial compartment noninvasively
over time. Therefore, there is a growing need for
imaging modalities that provide thorough neuropatho-
logical evaluations of xenograft and transgenic mod-
els of intracranial pathology. In this study, we have
established protocols for multiple-mouse magnetic
resonance imaging (MRI) to follow the growth and
behavior of intracranial xenografts of gliomas longi-
tudinally. We successfully obtained weekly images on
16 mice for a total of 5 weeks on a 7-T multiple-mouse
MRI. T2- and T1-weighted imaging with gadolinium
enhancement of vascularity was used to detect tumor
margins, tumor size, and growth. These experiments,
using 3D whole brain images obtained in four mice at
once, demonstrate the feasibility of obtaining repeat
radiological images in intracranial tumor models and
suggest that MRI should be incorporated as a
research modality for the investigation of intracranial
pathobiology.
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Introduction
Preclinical models of human diseases are vital for basic
and translational research, and an increasing number of
specific and genetically targeted spontaneous transgenic
intracranial glioma models are being developed [1] and
added to the established orthotopic xenograft models of
intracranial tumors. An important model for studying cen-
tral nervous system (CNS) tumors is in the intracranial
microenvironment, as the brain has several unique and
critical physiological attributes such as the blood–brain
barrier (BBB), vascularity, and extracellular matrix (ECM).
Orthotopic intracranial models of brain tumors provide
complimentary information to that obtained from subcuta-
neous xenograft models of brain cancer. Direct monitoring
and evaluation of the intracranial compartment, however, is
not readily possible. Therefore, there is a growing need for
imaging modalities used for screening that provide thorough
neuropathological evaluations of xenograft and transgenic
models of intracranial pathology.
Magnetic resonance imaging (MRI) is adept at investigating
intracranial models of brain cancer and is the best method of
following in vivo tumor growth longitudinally. Similar to the
established clinical role of MRI in the diagnosis and follow-up
of CNS neoplasia, small animal MRI is becoming established
as a research tool to image intracranial tumor models. MRI can
follow them longitudinally with accurate spatial localization to
ultimately develop more sensitive methods for characterizing
intracranial tumors and answer biological questions related to
their pathogenesis [2–5]. In addition to fundamental param-
eters such as tumor size, shape, and pattern of growth, small
animal MRI has the potential to monitor physiological param-
eters such as edema, invasion, angiogenesis, and responses
to various potential therapeutic interventions. To date, the
study numbers have been small because long imaging times
are needed to obtain high-resolution 3D images over the whole
brain in mice, even at high magnetic field strengths. The linear
scaling factor between mouse and human brain structures is
about 10; therefore, better the image resolution is required in
order to obtain images in a mouse brain that compare in the
level of structural detail to those of a human brain. For example,
a human clinical image with an in-plane resolution of 1  1
mm and a slice thickness of 5 mm would correspond to an in-
plane resolution of 100  100 mm and a slice thickness of 500
mm in an image of a mouse. A thorough screen should include a
relatively large number of animals to assess biological hetero-
geneity and it is important that the throughput of MRI is
improved.
In the simplest case, an MRI screen should measure tumor
take, location, and growth rate over the survival period of the
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model. The data gathered from an MRI screen can provide
information to characterize the models, such as tumor loca-
tion, the latency of tumor take, and anatomical limits of tumor
growth. This baseline information is essential for planning
future detailed MRI and histological studies, in addition to
testing the efficacy of therapeutic compounds. The screen
should also be noninvasive to minimize the impact of the MRI
procedure on the outcome of the study.
The difficulty, however, in using MRI for initial screening is
that, currently, very little is known about the MRI appearance
and behavior of intracranial tumor models in mice. Recent
reports show that different cell lines grown as intracranial
tumors can generate variable MRI signal appearances in
mouse tumors that also differ from the appearance of human
tumors seen in clinical MRI [3]. The differences in signal are
expected, as various astrocytoma cell lines will generate
tumors of variable genotype, phenotype, and histopathology.
This is a rapidly evolving field of research and future studies
will need to focus on establishing and characterizing the
underlying mechanisms of variability in MRI appearance
between various cell lines used to generate different intra-
cranial xenograft models, because this information is impor-
tant to allow accurate use of the models in imaging studies. It
should also be kept in mind that, to date, mouse imaging
studies are performed over a range of different MRI field
strengths, which further confounds the interpretation of
image contrast seen between different cell lines. Therefore,
a reasonable MRI survey screen that has a good temporal
resolution over the course of mouse survival is needed for
tumor models and accounts for possible tumor contrast
mechanisms with appropriately weighted imaging sequen-
ces (notably T2-weighted, T1-weighted, and T1-weighted
with contrast agent enhancement). Such a screen should
also image the entire brain at a resolution that is diagnosti-
cally comparable to human clinical MRI.
In order to fulfill the above requirements for studying both
orthotopic xenograft and transgenic models of intracranial
gliomas, we have performed an MRI screen in an orthotopic
xenograft model of astrocytoma to test a protocol for screen-
ing larger numbers of tumor-bearing mice. This preliminary
study had the technical goal of establishing an MRI screen to
characterize intracranial tumors and to guide future studies.
The model is based on an intracranial injection of the
established human malignant astrocytoma cell line U87 into
NODSCID mice. We also examined the use of MRI to
evaluate an altered physiological parameter; we used U87
cells with an altered expression of angiopoietins, an impor-
tant angiogenic cytokine family that we have shown to play a
significant role in regulating the vascularity and growth of
astrocytoma xenograft models (submitted for publication).
Angiopoietin-1 (Ang1) increases tumor vascularity and con-
fers growth advantage to tumors, whereas Angiopoietin-2
(Ang2) generates abnormal tumor vascularity without alter-
ing tumor growth. Ultimately, our objective is to determine the
effect of angiopoietins on tumor latency, tumor growth, and
vascularity using weekly longitudinal MRI, followed by his-
tology and microcomputed tomography (micro-CT). In this
study, we followed a total of 16 mice—four mice from each of
three groups (control tumor, Ang1 upregulated tumor, and
Ang2 upregulated tumor) plus a cohort of four age-matched
mice without tumors—over the 5-week survival curve for the
model to identify tumors with MRI and follow them longitudi-
nally. To properly characterize the tumors, we imaged the
whole brain with contiguous 2D multislice and 3D MRI
sequences to avoid the difficulty of 2D slices missing foci
or whole tumors. In general, the time needed for high-
resolution 3D imaging further limits the throughput of MRI,
but we were able to increase throughput in our study by using
our multiple-mouse MRI technique [6] to image groups of
four mice simultaneously. Extending our technique to image
a greater number of mice will enable high-throughput, high-
resolution serial screening with MRI in a variety of xenograft
and transgenic mouse models of brain cancer. The study is
an example of a typical mouse cancer MRI screen utilizing
3D whole brain images and spotlights the excellent sensitiv-
ity of MRI for following lesions longitudinally in vivo.
Materials and Methods
Cells and Reagents
Established U87 MG human astrocytoma cells were
obtained from the American Type Culture Collection (ATCC;
Rockville, MD) and maintained in Dulbecco’s minimal essen-
tial medium (DMEM; Cellgro, Herndon, VA) supplemented
with 10% FBS and penicillin–streptomycin antibiotics. Full-
length human ANG1 and ANG2 cDNA (a gift from K. Alitalo,
Helsinki, Finland) were subcloned into the pSec vector
(Invitrogen, Carlsbad, CA) to allow generation of Myc-Histi-
dine epitope-tagged constructs. The Ang-Myc/HIS sequence
was subcloned into the BamHI and EcoRI sites of a pCAGG
vector that contains a CMV promoter with a chicken b-actin
enhancer. Stable cell lines were generated by transfection of
the vector ‘‘pCAGG-Ang-Myc/HIS-Zeocin’’ into the U87 cell
line using Lipofectamine 2000 (Gibco/BRL, Gaithersburg,
MD) as per the manufacturer’s instructions. Twenty stable
clones, selected with 1 mg/ml Zeocin (Invitrogen), were
examined for Ang1 and Ang2 expression by Western blot
analysis. Two single clones with the highest expression of
Ang1 above baseline parental levels as well as one pooled
clone of Ang1 were selected. Similarly, for Ang2, one single
clone and one pooled clone with the strongest expression
were selected. For control clones, empty vector transfec-
tants were used.
Animals
All of the mice used in this study were maintained under
protocols approved by the Hospital for Sick Children, Tor-
onto. For the orthotopic astrocytoma model, established
human astrocytoma cells U87 (106 cells in DMEM media)
were implanted using a rodent stereotactic frame and a
Hamilton syringe 3 mm deep into the frontal cortex of
NODSCID mice. Stable U87 cell lines overexpressing either
Ang1 or Ang2 were injected similarly. For each of the three
cell types (U87 parental cell line for control tumors, U87 Ang1
upregulated cell line, and U87 Ang2 upregulated cell line)
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four mice were generated. Another four mice without cell
implantation were used as normal brain controls. The ani-
mals were followed clinically and when they exhibited symp-
toms consistent with failure to thrive as per animal care
protocols, they were sacrificed by perfusion fixation with
BrDU after an intravenous injection of 2% Evans Blue
solution (2 ml/kg) to analyze BBB status and vessel perme-
ability. The time interval between the injection of Evans Blue
and the perfusion and killing of mice was approximately 30
minutes. The brains were dissected and placed in formalin
for histopatholgical analysis.
MRI
MRI was performed on a 7-T scanner (Varian, Palo Alto,
CA) outfitted with four parallel receivers for multiple-mouse
imaging. Four mice were imaged together with an array of
four many-runged 3-cm inner diameter birdcage coils of
Varian’s Millipede design [7]. The imaging consisted of T2-
and T1-weighted sequences with a field-of-view (FOV)
covering the entire brain. The mice were mechanically
positioned in the scanner to obviate the need for scout scans
to locate their brains. Screening started 2 weeks after cell
injection with a T2-weighted sequence and continued every
week for 3 weeks. The T2-wieghted sequence was replaced
at week 4 with a weekly T1-weighted sequence that contin-
ued until the mice failed to thrive and were sacrificed. The
T2-weighted sequence was a multislice spin-echo sequence
with the slices placed in the coronal direction in the brain
[repetition time (TR) = 3000 milliseconds, echo time (TE) =
30 milliseconds, FOV: readout  phase = 512  128 =
80  20 mm, slice thickness = 0.5 mm, number of
averages (NEX) = 6, total imaging time = 38 minutes].
Because the TR needs to be several seconds long to
produce T2 weighting in the mouse brain [8], a multislice
sequence with contiguous slices was used instead of a 3D
sequence to reduce the imaging time. The T1-weighted
sequence used a 3D spin-echo sequence with the best
resolution in the horizontal plane (TR = 300 milliseconds,
TE = 10 milliseconds, Fov:readout  phase  phase =
256  128  32 = 40  20  16 mm, NEX =1, total
imaging time = 21 minutes). The T1-weighted sequence
was applied once without contrast, then again 20 minutes
after a tail vein injection of 0.1 mM/kg gadopentetate
dimeglumine contrast agent (Berlex, Lachine PQ). Tem-
perature, electrocardiogram (ECG), and breathing rate in
the four mice were monitored using a custom-built system.
The mice were anesthesized during imaging with 1%
isofluorane in O2 delivered by nose cones, and were
warmed with hot air to control their temperatures.
Histopathology
Fixed brains were paraffin-embedded, sectioned (4 mm),
and examined histologically using hematoxylin and eosin
(H&E) stains together with immunohistochemical staining
for Factor VIII to mark endothelial cells. Histological exami-
nations were performed on sections corresponding to the
location of lesions seen on MRI.
Micro-CT
One mouse with a developed control U87 tumor was
selected for micro-CT imaging of contrast agent– loaded
vessels based on a T1-wieghted image with contrast agent
enhancement. It was anesthesized by an intraperitoneal
injection of ketamine (50 mg/kg) and xylazine (10 mg/kg).
Following a 500-U subcutaneous injection of heparin, the
mouse’s chest was opened and another solution of heparin
(1 U/ml) and physiologically buffered saline at 37j C was
injected through the left ventricle and drained from the right
atrium to replace the blood. This was followed by an infusion
of Microfil MV-122 (Flow Tech Inc., Carver, MA), a silicone
rubber compound with a viscosity initially comparable to
blood, that begins to harden 30 minutes after injection. The
brain was excised and stored at 4j C in a solution of 10%
neutral-buffered formalin. The infused Microfil was allowed to
cure over a period of 12 hours and was the source of contrast
in the resulting micro-CT image. All fluids were infused at a
constant pressure of 160 mm Hg (21.3 kPa) to preserve
physiological vessel caliber.
A 3D CT data set was acquired for the excised brain using
an MS-8 micro-CT scanner (GE Medical Systems, London,
Ontario, Canada) (submitted for publication). With the X-ray
source at 80 kVp (mean energy of incident beam: 32 keV),
the image was acquired in 2.5 hours with 900 views and
reconstructed using the Feldkamp algorithm [9] for cone
beam CT geometry. The vasculature in the image was
segmented using a simple thresholding algorithm and its
surface was rendered. The computed image shows both
arterial and venous vessels as highly intense regions of a
signal against a relatively uniform background with a low
signal. Regions where the contrast agent has leaked into the
extravascular space also have a high signal intensity.
Results
Feasibility of Longitudinal MRI Studies
One purpose of this study was to determine the effect of
our high-throughput MRI screen on the outcome and overall
survival of the mice. The mice tolerated the 2-hour anes-
thetic period required for the entire MRI procedure well at
each time point despite harboring large mass-occupying
lesions in the brain. The pooled overall survival of tumor-
bearing mice included in the MRI screen was (33 ± 1 days),
which was the same as the survival of tumor-bearing mice
not included in the MRI screen (36 ± 5 days). These results
confirm and clearly demonstrate the feasibility of using MRI
for follow-up of tumor growth in mouse models of intracra-
nial tumors and that it is not detrimental to the outcome and
survival of mice.
Tumor Characterization
A second purpose of this study was to determine if we
could detect tumors using MRI over the course of survival of
the mice and characterize the MRI appearance of these
tumors. We began weekly imaging 2 weeks postimplantation
using T2-weighted sequences as T2 sequences are often
548 MRI as a Screening Tool for Brain Tumor Models Bock et al.
Neoplasia . Vol. 5, No. 6, 2003
used to delineate the extent of tumor mass and tumor-
associated edema from normal brain tissues, although even
clinically, the problem of delineating tumor mass from tumor-
associated edema remains an unsolved problem. A technical
advantage is that T2-weighted sequences require only one
set of images and no intravenous injection of contrast agent
(instead of two sets of images and an injection for the
T1-weighted sequence). We used images from age-matched
mice without tumors to distinguish lesions from normal
anatomy in the images of tumor-bearing mice. Previous
growth rate curves in a similar tumor model from conven-
tional pathology [10] showed tumor take between weeks 2
and 3 postimplantation; thus, we chose week 2 as our first
time point for imaging and followed the mice weekly for 3
weeks with T2-weighted images. We began T1-weighted
imaging with and without contrast agent at week 5 to assess
the extent of tumor vascularization and vessel permeability in
the larger tumors at week 5. Table 1 summarizes the
appearance of lesions during the screen in the tumor-bearing
mice and Figure 1 shows the typical tumor appearance in
one control U87 tumor mouse at each weekly time point.
Hypointense lesions were seen in 7 of 11 mice on the first
T2-weighted image (week 2). Endogenous tumor enhance-
ment was not seen in any of the mice in the T1-weighted
images; however, with injection of the contrast agent, eight of
nine mice had lesion enhancement. The lesions detected on
the MRI images were confirmed to be tumors by both Evans
Blue demarcation and histology at necropsy for each mouse.
We did not confirm whether the tail vein injection of the
contrast agent was consistent in all of the mice; thus, one
mouse that did not show lesion enhancement on its
T1-weighted image might not have had an adequate con-
centration of gadolinium in its blood.
Tumor Variability
Tumor contrast arises in T1-weighted images following an
injection of a gadolinium contrast agent because of the
increased density of blood vessels in the tumor and because
the agent leaks from tumor vessels that have a compromised
BBB. Another technique that stains tumors with a compro-
mised BBB and that can be used to see the extent of tumors
in excised brains is an injection of Evans Blue dye. Figure 2A
shows a photograph of a tumor stained with the established
Evans Blue technique in the excised brain of a mouse and
Figure 2B shows a T1-weighted MRI image with a volume-
rendered region of contrast agent enhancement in the same
mouse before it was sacrificed. The two methods are in good
visual agreement, although the MRI provides a much better
3D characterization of the extent and location of the tumor
and can be used to make accurate volume measurements.
Figure 3 shows volume-rendered regions of enhancement in
four tumor-bearing mice that were imaged together 5 weeks
postinjection and reveals overall variability in the size and
shape of individual tumors. The advantage of using a 3DMRI
image over the whole brain is clear from Figure 3—the
complex extent and precise margins of the tumors would
be impossible to characterize in a single MRI slice and would
be misrepresented if multiple slices that were not contiguous
were used.
Ventricle Size
In addition to characterizing tumor lesions, MRI can also
be used to detect other neuropathological abnormalities
that arise directly or indirectly as a result of the glioma that
might be missed on histological evaluation alone. Because
T2-weighted images show cerebrospinal fluid (CSF) and
major brain structures well, they are good for identifying
abnormalities in the brain [11]. An unexpected finding in
our study was the presence of enlarged ventricles seen
early and throughout the 5-week period of the study in all
mice bearing Ang1 upregulated tumors (Figure 4). The
ventricle dilatation was a pan-ventriculomegaly and no
evidence of CSF obstruction or tumor growth in the ven-
tricles was seen. As well, the dilatation was not related to
tumor size, location, morphology, or pattern of tumor cell
invasion. Additionally, ventriculomegaly was only seen with
the Ang1 upregulated tumors and not seen in control or
Ang2 upregulated tumors. This finding suggests that the
dilatation of ventricles was related to the biological effects
of Ang1—potentially an interference with CSF absorption.
This was an interesting and unexpected finding that illus-
trates the strengths and benefits of whole brain imaging for
intracranial tumor models and also reveals that care must
be taken when comparing external measures of tumor
aggressiveness because the behavior, growth, and clinical
survival of mice with Ang1 upregulated tumors will be
affected by hydrocephalus.
Micro-CT
Finally, we used MRI to select an appropriate tumor-
bearing mouse for detailed micro-CT to test this novel ap-
proach for visualizing and analyzing brain tumor vasculature.
Themicro-CT technique produces high-resolution 3D images
with 20-mm isotropic voxels of the distribution of a blood
contrast agent in the excised brain from a mouse. Figure 5
shows an example of a slice from the T1-weighted scan in the
mouse and the surface-rendered vasculature of the mouse
from the micro-CT data, demonstrating good visual agree-
ment of the lesions between the two modalities. This image
highlights potential future areas of research and study using
micro-CT. We can generate high-resolution 3D images of
brain and tumor vasculature and those data sets can be
registered to MRI images of the mouse brain using computer
software to help interpret how the underlying vascular struc-
ture contributes to contrast mechanisms in tumors.
Table 1. Lesion Appearance on Week 2 T2-Weighted Images and on Week
5 T1-Weighted Images Following Administration of a Contrast Agent.
Lesion Appearance Number of Mice
Hypointense only on T2 7/11
Hyperintense only on T2 1/11
Heterogeneous on T2 2/11
Hyperintense on T1 with contrast agent 8/9
All mice had confirmed tumors on histology.
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Discussion
In this study, we successfully identified tumors in the four
groups of mice over the course of their survival using both
T2- and T1-weighted images. The early T2-weighted images
showed lesions that were predominantly hypointense, with
minimal heterogeneity seen in the signal. The hypointense
T2 lesions seen in this study are most likely related to the
specific characteristics of U87 tumors implanted in mice and
the image characteristics will most likely vary with the tumor
cell line used to generate orthotopic intracranial xenografts.
A recent study [5] shows hyperintense T2 lesions as op-
posed to the predominantly hypointense lesions we saw, and
this highlights the need for further investigation and charac-
terization of individual cell lines used in experimental studies
and for understanding the underlying mechanisms of vari-
ability in MRI appearance between different intracranial
xenograft models to allow accurate and valuable incorpora-
tion of MRI images as a routine research modality. We have
histologically confirmed the presence of tumors in the loca-
tion of hypointense T2 lesions seen at week 2 in all mice. The
T2-weighted images were also useful for detecting and
following the additional unpredicted pathology of hydroceph-
alus in mice with Ang1 upregulated tumors.
T1 weighting with the contrast agent injection produced
good contrast at later time points that corresponded with
conventional methods of identifying vascular regions of
tumors. Because the mice tolerated the screening well, we
will extend the imaging time in future screens and studies so
that we can image with both T1 and T2 weighting at each
time point. Because T1 weighting requires an injection of
contrast agent for each week, we are exploring a method of
catheterization [12] or an intraperitoneal injection of contrast
agent [13]. Our first ever micro-CT image of mouse intracra-
nial tumor vasculature (Figure 5) shows promise for this
technique as a research tool to compliment present methods
of analyzing tumor vascularity.
One major finding in this study was that despite estab-
lished and standardized stereotactic methods of intracranial
glioma cell implantation, there was a marked variability in the
extent and pattern of tumor growth (Figure 3). Variability is an
important finding as it sheds light on the pattern of cell
invasion and has implications for use of the model for
Figure 1. A time course of MRI images in a single U87 control mouse. The in-plane resolution of MRI images is 156 m and the slices are 500 m thick. One slice
from the 3D data set for each time point is shown as well as a slide from histology that confirms the presence of a tumor at the final time point.
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therapeutic studies. The variability in tumor growth, however,
means that it is difficult to construct statistically meaningful
growth rate curves using a small cohort of mice. From this
study, we can conclude that larger numbers of mice have to
be included in MRI screens to overcome the high degree of
variability in tumor growth and to statistically analyze and
Figure 2. (A) A photograph of the excised brain from a mouse stained for tumor vasculature with Evans Blue dye. (B) A 3D T1-weighted MRI image from the same
mouse before it was sacrificed with a volume-rendered region of contrast enhancement.
Figure 3. Volume-rendered regions of enhancement on 3D T1-weighted images of four tumor-bearing mice imaged together at the same time point 5 weeks
postinjection.
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compare tumor growth rates between different groups of
mice. Additionally, in this study, we were unable to accurately
interpret tumor volume changes between control, Ang1 and
Ang2 tumor groups because the T2-weighted sequences
used at earlier time points in the study did not provide precise
tumor delineation. Overall, based on this pilot study for future
studies, both T1- and T2-weighted sequences should be
undertaken at each time point.
Figure 4. (A) Ventricle size over time in four groups of age- and sex-matched NODSCID mice (n = 4) measured from T2-weighted MRI images. The ventricles in
each 3D data set were manually segmented with in-house image analysis software and their volumes were calculated. (B) Representative images from two slices
from each group of mice.
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In an attempt to address the issue of larger numbers of
mice being imaged by MRI in a reasonable time frame, we
increased throughput in this study by a factor of four using
our multiple-mouse technique. To date, there has been only
one study by Xu et al. [14] that has also demonstrated a
multiple-mouse screening technique; however, the low sen-
sitivity in their experiment from using a single large radio-
frequency coil loaded with many mice meant that the imaging
was only suitable for detecting late tumors just before they
were large enough to impact the physiological functions of
the mice. Nelson et al. [11] and Cha et al. [3] have both
recently shown the excellent sensitivity of single-mouse
high-field MRI for screening and following tumors from a
much earlier stage of development. The advantage of our
multiple-mouse technique is that it produces similar high-
quality images but with a much higher throughput.
The results of this study suggest that a useful MRI screen
for intracranial tumor models consists of weekly high-resolu-
tion 3D whole brain imaging with T2 and T1 weighting with
contrast agent injection using a high-field multiple-mouse
MRI system. Although this might not be a universal screen
for all transgenic and xenograft tumor models (the MRI might
not be sensitive to some tumors), it provides a thorough and
simple approach to longitudinal screening. We have demon-
strated that longitudinal weekly MRI is a feasible method of
following tumor growth and believe that it should be a major
research tool for studying intracranial tumor biology in both
xenograft and transgenic mouse models.
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